Baseline characteristics
| Characteristic . | R-B (n = 97) . | R-CHOP/R-DHAP (n = 232) . | P . |
|---|---|---|---|
| Median year (range) | 2016 (2012-2020) | 2007 (2004-2010) | <.001 |
| Age, y | |||
| Median (range) | 58 (40-65) | 56 (32-65) | <.001 |
| Age ≥ 60, n (%) | 42 (43) | 64 (27) | .004 |
| Male sex, n (%) | 60 (62) | 183 (79) | .001 |
| Ann Arbor stage, n (%) | .17 | ||
| II | 4 (4) | 10 (4) | |
| III | 6 (6) | 31 (13) | |
| IV | 87 (90) | 191 (82) | |
| Bone marrow involvement, n (%) | 76 (78) | 173 (75) | .47 |
| B symptoms, n (%) | 11/78 (14) | 71 (31) | .004 |
| ECOG performance status, n (%) | <.001 | ||
| 0 | 30 (31) | 150 (65) | |
| 1 | 54 (56) | 73 (32) | |
| 2 | 13 (13) | 9 (4) | |
| Lactate dehydrogenase | |||
| Lactate dehydrogenase/upper limits of normal ratio (range) | 0.81 (0.41-3.26) | 0.89 (0.41-12.2) | .30 |
| Elevated, n (%) | 27 (28) | 81 (35) | .21 |
| WBC count × 109/L (range) | 7.0 (3.1-136) | 7.6 (1.1-323.8) | .34 |
| MIPI | |||
| MIPI score (range) | 5.65 (4.58-7.82) | 5.56 (4.07-8.68) | .089 |
| MIPI risk category, n(%) | .16 | ||
| Low risk | 53 (55) | 150 (65) | |
| Intermediate risk | 24 (25) | 51 (22) | |
| High risk | 20 (21) | 31 (13) | |
| Blastoid/pleomorphic, n (%) | 7 (7) | 14/169 (8) | .76 |
| Ki67 index | |||
| Median (range) | 25 (5-90) | 21 (1.5-95) | .14 |
| ≥30%, n (%) | 40/89 (45) | 34/129 (26) | .004 |
| MCL35 risk group, n (%) | .60 | ||
| Low risk | 27/50 (54) | 21/36 (58) | |
| Standard risk | 17/50 (34) | 13/36 (36) | |
| High risk | 6/50 (12) | 2/36 (6) | |
| Characteristic . | R-B (n = 97) . | R-CHOP/R-DHAP (n = 232) . | P . |
|---|---|---|---|
| Median year (range) | 2016 (2012-2020) | 2007 (2004-2010) | <.001 |
| Age, y | |||
| Median (range) | 58 (40-65) | 56 (32-65) | <.001 |
| Age ≥ 60, n (%) | 42 (43) | 64 (27) | .004 |
| Male sex, n (%) | 60 (62) | 183 (79) | .001 |
| Ann Arbor stage, n (%) | .17 | ||
| II | 4 (4) | 10 (4) | |
| III | 6 (6) | 31 (13) | |
| IV | 87 (90) | 191 (82) | |
| Bone marrow involvement, n (%) | 76 (78) | 173 (75) | .47 |
| B symptoms, n (%) | 11/78 (14) | 71 (31) | .004 |
| ECOG performance status, n (%) | <.001 | ||
| 0 | 30 (31) | 150 (65) | |
| 1 | 54 (56) | 73 (32) | |
| 2 | 13 (13) | 9 (4) | |
| Lactate dehydrogenase | |||
| Lactate dehydrogenase/upper limits of normal ratio (range) | 0.81 (0.41-3.26) | 0.89 (0.41-12.2) | .30 |
| Elevated, n (%) | 27 (28) | 81 (35) | .21 |
| WBC count × 109/L (range) | 7.0 (3.1-136) | 7.6 (1.1-323.8) | .34 |
| MIPI | |||
| MIPI score (range) | 5.65 (4.58-7.82) | 5.56 (4.07-8.68) | .089 |
| MIPI risk category, n(%) | .16 | ||
| Low risk | 53 (55) | 150 (65) | |
| Intermediate risk | 24 (25) | 51 (22) | |
| High risk | 20 (21) | 31 (13) | |
| Blastoid/pleomorphic, n (%) | 7 (7) | 14/169 (8) | .76 |
| Ki67 index | |||
| Median (range) | 25 (5-90) | 21 (1.5-95) | .14 |
| ≥30%, n (%) | 40/89 (45) | 34/129 (26) | .004 |
| MCL35 risk group, n (%) | .60 | ||
| Low risk | 27/50 (54) | 21/36 (58) | |
| Standard risk | 17/50 (34) | 13/36 (36) | |
| High risk | 6/50 (12) | 2/36 (6) | |